Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Urinary Bladder Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Osteosarcoma 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Malignant Solid Neoplasm 1Lymphoma 1Histiocytic Sarcoma 1Familial ependymoma 1Carcinoma, Transitional Cell 1Breast Neoplasms 1Advanced Solid Tumor 1

Interventions

Gemcitabine 4Cisplatin 4Carboplatin 3pembrolizumab 2erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1enfortumab vedotin 1avelumab 1Sunitinib 1Radiotherapy 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Docetaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Urothelial Cancer × erdafitinib × Clear all
NCT02365597 2026-06-05

An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer

Janssen Research & Development, LLC

Phase 2 Active not recruiting
239 enrolled 32 charts 1 FDA
Genitourinary

Urothelial Cancer

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting
629 enrolled 32 charts
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡